Agilent Technologies
30-Second Executive Brief
Executive Assessment
Agilent Technologies functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, though its relative influence is cooling.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A life-science instruments and laboratory informatics company that raised its fiscal year 2026 revenue guidance to $7.39-$7.49 billion (6.3-7.8% reported growth) after Q2 FY2026 revenue reached $1.83 billion (up 10.0% reported, 6.3% core). Agilent announced a $950 million acquisition of Biocare to expand its clinical and research offerings, expanding lab informatics with OpenLab Sync alongside new chromatography and mass spectrometry systems, and showcased cancer research and diagnostics technologies at AACR 2026.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Health and Human Services — $856,028: TRIPLE SPEC MASS SPECTROMETERS
USAspending.gov · Sep 12, 2014
Department of Homeland Security — $7,498,510: THE PURPOSE OF THIS CONTRACT IS TO PURCHASE AGILENT BULK RESOLUTION TECHNOLOGY (BRT) UNITS AND ASSOCIATED MAINTENANCE.
USAspending.gov · Sep 30, 2025
Department of Homeland Security — $4,346,040: TO FURTHER DEVELOP AND PROCURE BULK RESOLUTION TECHNOLOGY (BRT) UNITS TO SUPPORT RESEARCH AND DEVELOPMENT (R&D) AND TESTING REQUIREMENTS.
USAspending.gov · Sep 30, 2024
Department of Health and Human Services — $1,947,631: SERVICE AND MAINTENANCE AGREEMENT FOR AGILENT TECHNOLOGIES, INC.
USAspending.gov · Apr 3, 2026
Department of Homeland Security — $1,242,120: GC/MS SYSTEM
USAspending.gov · Sep 26, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Simply Wall St — Agilent Technologies is up 17.9% after raising 2026 outlook and expanding lab informatics portfolionews
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Insider Timing
An insider disposed of 1,600 shares on May 29, 2026 — 28 days after a recorded milestone: “Raises FY2026 guidance after Q2 results”
Timing correlation only — not evidence of a causal link
An insider acquired 8,872 shares on May 19, 2026 — 18 days after a recorded milestone: “Raises FY2026 guidance after Q2 results”
Timing correlation only — not evidence of a causal link
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Agilent Technologies — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
The Biocare deal is Agilent buying into clinical diagnostics adjacency rather than just expanding instruments
29% confidenceAgilent raised FY2026 revenue guidance following a Q2 revenue beat and simultaneously announced a $950 million acquisition of Biocare to expand its clinical and research offerings, alongside organic lab informatics launches like OpenLab Sync.
This is InsightNodes' own interpretive read: pairing an acquisition-funded push into clinical offerings with raised guidance suggests management is confident enough in current core momentum to simultaneously integrate a sizable deal, but it also means near-term execution risk is now split across both an M&A integration and continued organic growth expectations -- if core instrument demand from academic and pharma R&D softens, the Biocare integration would have less cushion to absorb execution missteps than if it had been pursued from a position of excess capacity rather than concurrent with raised guidance.
InsightNodes analysis of Agilent's Biocare acquisition · Aug 14, 2026
Agilent Technologies's Timeline
A sourced, dated history of Agilent Technologies's key moments — founding to present.
Apr 2026 · Announces $950M Biocare acquisition
Agilent announced a $950 million acquisition of Biocare to expand its clinical and research offerings, with integration expected upon closing in fiscal year 2026.
May 2026 · Raises FY2026 guidance after Q2 results
Agilent raised its fiscal year 2026 revenue guidance to $7.39-$7.49 billion after Q2 FY2026 revenue reached $1.83 billion, up 10.0% reported and 6.3% core.